Research

Hormonal

In patients with a BMI ≥40, fracture risk was significantly increased with GLP-1RA use (3.15% vs. 1.91%, OR 1.26, CI [1.04 to 1.52]).

Higher BMI patients may require closer monitoring for fracture risk when prescribed GLP-1RAs.

StrongSupportsmedium confidence
Subanalyses based on body mass index (BMI) and age group demonstrated increased fracture risk in the GLP-1RA group in patients with a BMI ≥40 (3.15% vs. 1.91%, NNH = 81, OR 1.26, CI [1.04 to 1.52]).
Evangelia Constantine et al. · Journal of the American Academy of Orthopaedic Surgeons · 2025

Why this rating

Based on a large retrospective case-control study design.

Source

The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Fracture Risk in Overweight or Obese, Nondiabetic Patients

Evangelia Constantine et al. · Journal of the American Academy of Orthopaedic Surgeons · 2025

DOI 10.5435/jaaos-d-24-01505

cohort · n=606364Cited 3×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →